How to Buy lalpathlab Shares on Fincept?
You can buy Dr. Lal PathLabs Limited shares on Different Brokers & Banks by creating an account and completing KYC verification online.
NSE: Dr. Lal PathLabs Limited Share Price Today, Share Analysis, Latest Updates & Insights | Fincept
Stay informed with the latest announcements for Lalpathlab, including updates on board meetings and corporate actions.
Dr. Lal PathLabs Limited - https://www.lalpathlabs.com
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.
Dr. Lal PathLabs Limited Share Price Today
2,759.00
OPEN
2,891.95
HIGH
2,754.95
LOW
2,877.85
CLOSE
952 K
VOLUME
24,950 Cr
Market Cap
192957
Average Volume
Healthcare
Sector
NSI
Exchange
Dr. Lal PathLabs Limited Share Analysis & 2025 Insights
Investor Presentations
| Date | Description | Download |
|---|
SIP
Lumpsum
Invested Amount: ₹
Estimated Returns: ₹
Total Value: ₹
NSE: LALPATHLAB Stock Actions
Company |
Symbol |
ISIN |
Subject |
Ex Date |
Face Value |
Broadcast Date |
|---|---|---|---|---|---|---|
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
INE600L01024 |
Interim Dividend - Rs 6 Per Share |
05 Nov 2024 |
10 |
N/A |
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
INE600L01024 |
Interim Dividend - Rs 6 Per Share |
20 Aug 2024 |
10 |
N/A |
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
INE600L01024 |
Dividend - Rs 6 Per Share |
10 Jun 2024 |
10 |
N/A |
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
INE600L01024 |
Interim Dividend - Rs 12 Per Share |
13 Feb 2024 |
10 |
N/A |
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
INE600L01024 |
Interim Dividend - Rs 6 Per Share |
11 Aug 2023 |
10 |
N/A |
NSE: LALPATHLAB Recent Announcements
Symbol |
Date |
Description |
Industry |
|---|---|---|---|
LALPATHLAB |
31 Dec 2024, 20:38:15 |
Updates |
N/A |
LALPATHLAB |
26 Dec 2024, 10:25:51 |
Trading Window-XBRL |
N/A |
LALPATHLAB |
26 Dec 2024, 10:21:14 |
Trading Window |
N/A |
LALPATHLAB |
18 Dec 2024, 13:16:48 |
Alteration Of Capital and Fund Raising-XBRL |
N/A |
LALPATHLAB |
18 Dec 2024, 13:03:59 |
Allotment of Securities |
N/A |
NSE: LALPATHLAB Corporate Governance
Name |
Symbol |
Timestamp |
Submission Date |
XBRL Document |
|---|---|---|---|---|
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
16 Oct 2024, 12:39:00 |
16 Oct 2024, 12:39:00 |
|
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
11 Jul 2024, 14:46:00 |
11 Jul 2024, 14:46:00 |
|
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
15 Apr 2024, 18:13:00 |
15 Apr 2024, 18:30:00 |
|
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
15 Jan 2024, 16:45:00 |
15 Jan 2024, 17:15:00 |
|
Dr. Lal Path Labs Ltd. |
LALPATHLAB |
18 Oct 2023, 12:00:00 |
18 Oct 2023, 12:30:00 |
NSE: LALPATHLAB Detailed Governance
Category |
Date of Birth |
Date of Initial Appointment |
DIN |
Director Name |
Status |
|---|---|---|---|---|---|
Chairperson Related To Promoters,Executive Director |
22 Aug 1949 |
14 Feb 1995 |
00576638 |
Arvind Lal |
Active |
Non-Executive Director |
23 Apr 1981 |
17 May 2019 |
08432506 |
Archana Lal Erdmann |
Active |
Independent Director |
01 Oct 1946 |
02 Feb 2023 |
00024262 |
Arun Duggal |
Active |
Independent Director |
15 Dec 1965 |
27 Jul 2023 |
10197218 |
Gurinder Singh Kalra |
Active |
Executive Director-MD |
30 Aug 1965 |
01 Feb 2011 |
02099404 |
Om Prakash Manchanda |
Active |
NSE: LALPATHLAB Board Meetings
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
|---|---|---|---|---|---|
DR. LAL PATH LABS LTD. has informed the Exchange about Board Meeting to be held on 23-Oct-2024 to consider and approve the Half Yearly Unaudited Financial results of the Company for the period ended September 2024 and Dividend/Other business. |
LALPATHLAB |
N/A |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
16 Oct 2024, 12:06:09 |
DR. LAL PATH LABS LTD. has informed the Exchange about Board Meeting to be held on 07-Aug-2024 to consider and approve the Quarterly Unaudited Financial results of the Company for the period ended June 2024 and Dividend/Other business. |
LALPATHLAB |
N/A |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
31 Jul 2024, 11:09:19 |
DR. LAL PATH LABS LTD. has informed the Exchange about Board Meeting to be held on 10-May-2024 to consider and approve the Yearly Audited Financial results of the Company for the period ended March 2024 and Dividend/Other business. |
LALPATHLAB |
N/A |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
03 May 2024, 11:17:06 |
Financial Results/Dividend/Other business matters |
LALPATHLAB |
N/A |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
25 Jan 2024, 10:28:03 |
Financial Results/Other business matters |
LALPATHLAB |
N/A |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
25 Oct 2023, 15:55:02 |
NSE: LALPATHLAB Event Calendar
Purpose |
Symbol |
Industry |
ISIN |
Name |
Time |
Description |
|---|---|---|---|---|---|---|
Financial Results/Dividend/Other business matters |
LALPATHLAB |
- |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
16 Oct 2024, 00:00:00 |
To consider and approve the un-audited financial results (Standalone and Consolidated) for the period ended September 30, 2024, dividend, if any and other business matters |
Financial Results/Dividend/Other business matters |
LALPATHLAB |
- |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
31 Jul 2024, 00:00:00 |
To consider and approve the financial results for the period ended Jun 30, 2024, dividend and other business matters |
Financial Results/Dividend/Other business matters |
LALPATHLAB |
- |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
03 May 2024, 00:00:00 |
To consider and approve the financial results for the period ended March 31, 2024, recommendation of final dividend, if any and other business matters |
Financial Results/Dividend/Other business matters |
LALPATHLAB |
- |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
25 Jan 2024, 00:00:00 |
To consider and approve the financial results for the period ended December 31, 2023, dividend and other business matters |
Financial Results/Other business matters |
LALPATHLAB |
- |
INE600L01024 |
Dr. Lal Path Labs Ltd. |
25 Oct 2023, 00:00:00 |
To consider and approve the Unaudited financial results for the Quarter and Half Year ended September 30, 2023 and other business matters |
NSE: LALPATHLAB Balance Sheet Data In (Cr)
| date | period_type | Treasury Shares Number | Ordinary Shares Number | Share Issued | Total Debt | Tangible Book Value | Invested Capital | Working Capital | Net Tangible Assets | Capital Lease Obligations | Common Stock Equity | Total Capitalization | Total Equity Gross Minority Interest | Minority Interest | Stockholders Equity | Other Equity Interest | Treasury Stock | Retained Earnings | Additional Paid In Capital | Capital Stock | Common Stock | Total Liabilities Net Minority Interest | Total Non Current Liabilities Net Minority Interest | Preferred Securities Outside Stock Equity | Non Current Deferred Taxes Liabilities | Long Term Debt And Capital Lease Obligation | Long Term Capital Lease Obligation | Long Term Debt | Current Liabilities | Other Current Liabilities | Current Debt And Capital Lease Obligation | Current Capital Lease Obligation | Current Debt | Pensionand Other Post Retirement Benefit Plans Current | Current Provisions | Payables | Other Payable | Total Tax Payable | Accounts Payable | Total Assets | Total Non Current Assets | Other Non Current Assets | Non Current Prepaid Assets | Non Current Deferred Taxes Assets | Investmentin Financial Assets | Available For Sale Securities | Investment Properties | Goodwill And Other Intangible Assets | Other Intangible Assets | Goodwill | Net PPE | Accumulated Depreciation | Gross PPE | Construction In Progress | Other Properties | Machinery Furniture Equipment | Buildings And Improvements | Land And Improvements | Properties | Current Assets | Other Current Assets | Restricted Cash | Prepaid Assets | Inventory | Other Inventories | Raw Materials | Other Receivables | Accounts Receivable | Allowance For Doubtful Accounts Receivable | Gross Accounts Receivable | Cash Cash Equivalents And Short Term Investments | Other Short Term Investments | Cash And Cash Equivalents | Cash Equivalents | Cash Financial | Net Debt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30T00:00:00 | quarterly | 277,866.00 | 83,296,386.00 | 83,574,252.00 | 1,985,000,000.00 | 11,742,000,000.00 | 20,433,000,000.00 | 8,632,000,000.00 | 11,742,000,000.00 | 1,568,000,000.00 | 20,016,000,000.00 | 20,016,000,000.00 | 20,352,000,000.00 | 336,000,000.00 | 20,016,000,000.00 | 19,180,000,000.00 | 0.00 | 0.00 | 0.00 | 836,000,000.00 | 836,000,000.00 | 5,623,000,000.00 | 999,000,000.00 | 0.00 | 31,000,000.00 | 968,000,000.00 | 968,000,000.00 | 0.00 | 4,624,000,000.00 | 364,000,000.00 | 1,017,000,000.00 | 600,000,000.00 | 417,000,000.00 | 0.00 | 299,000,000.00 | 2,411,000,000.00 | 0.00 | 287,000,000.00 | 2,124,000,000.00 | 25,975,000,000.00 | 12,719,000,000.00 | 33,000,000.00 | 0.00 | 448,000,000.00 | 258,000,000.00 | 258,000,000.00 | 335,000,000.00 | 8,274,000,000.00 | 2,790,000,000.00 | 5,484,000,000.00 | 3,291,000,000.00 | 0.00 | 3,291,000,000.00 | 14,000,000.00 | 3,277,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 13,256,000,000.00 | 270,000,000.00 | 0.00 | 0.00 | 468,000,000.00 | 0.00 | 0.00 | 10,000,000.00 | 901,000,000.00 | 0.00 | 0.00 | 11,607,000,000.00 | 10,539,000,000.00 | 1,068,000,000.00 | 0.00 | 0.00 | 0.00 |
| 2024-03-31T00:00:00 | quarterly | 264,775.00 | 83,213,077.00 | 83,477,852.00 | 2,469,300,000.00 | 9,967,880,000.00 | 19,326,170,000.00 | 6,615,090,000.00 | 9,967,880,000.00 | 1,635,960,000.00 | 18,492,830,000.00 | 18,492,830,000.00 | 18,853,640,000.00 | 360,810,000.00 | 18,492,830,000.00 | 511,500,000.00 | 143,900,000.00 | 15,085,170,000.00 | 1,058,360,000.00 | 834,780,000.00 | 834,780,000.00 | 5,705,990,000.00 | 1,054,110,000.00 | 0.00 | 23,920,000.00 | 1,030,190,000.00 | 1,030,190,000.00 | 0.00 | 4,651,880,000.00 | 348,000,000.00 | 1,439,110,000.00 | 605,770,000.00 | 833,340,000.00 | 378,710,000.00 | 379,000,000.00 | 2,148,020,000.00 | 149,490,000.00 | 132,860,000.00 | 1,865,670,000.00 | 24,559,630,000.00 | 13,292,660,000.00 | 7,030,000.00 | 124,120,000.00 | 448,590,000.00 | 192,500,000.00 | 192,500,000.00 | 337,050,000.00 | 8,524,950,000.00 | 3,043,100,000.00 | 5,481,850,000.00 | 3,483,980,000.00 | -4,479,420,000.00 | 7,963,400,000.00 | 53,710,000.00 | 3,430,000,000.00 | 3,288,350,000.00 | 4,351,510,000.00 | 269,830,000.00 | 0.00 | 11,266,970,000.00 | 196,000,000.00 | 14,900,000.00 | 351,530,000.00 | 373,070,000.00 | 0.00 | 373,070,000.00 | 327,500,000.00 | 774,020,000.00 | -314,880,000.00 | 1,088,900,000.00 | 9,425,950,000.00 | 5,816,620,000.00 | 3,609,330,000.00 | 3,360,550,000.00 | 248,780,000.00 | 0.00 |
| 2024-03-31T00:00:00 | annual | 264,775.00 | 83,213,077.00 | 83,477,852.00 | 2,469,300,000.00 | 9,967,880,000.00 | 19,326,170,000.00 | 6,615,090,000.00 | 9,967,880,000.00 | 1,635,960,000.00 | 18,492,830,000.00 | 18,492,830,000.00 | 18,853,640,000.00 | 360,810,000.00 | 18,492,830,000.00 | 511,500,000.00 | 143,900,000.00 | 15,085,170,000.00 | 1,058,360,000.00 | 834,780,000.00 | 834,780,000.00 | 5,705,990,000.00 | 1,054,110,000.00 | 0.00 | 23,920,000.00 | 1,030,190,000.00 | 1,030,190,000.00 | 0.00 | 4,651,880,000.00 | 348,000,000.00 | 1,439,110,000.00 | 605,770,000.00 | 833,340,000.00 | 378,710,000.00 | 379,000,000.00 | 2,148,020,000.00 | 149,490,000.00 | 132,860,000.00 | 1,865,670,000.00 | 24,559,630,000.00 | 13,292,660,000.00 | 7,030,000.00 | 124,120,000.00 | 448,590,000.00 | 192,500,000.00 | 192,500,000.00 | 337,050,000.00 | 8,524,950,000.00 | 3,043,100,000.00 | 5,481,850,000.00 | 3,483,980,000.00 | -4,479,420,000.00 | 7,963,400,000.00 | 53,710,000.00 | 3,430,000,000.00 | 3,288,350,000.00 | 4,351,510,000.00 | 269,830,000.00 | 0.00 | 11,266,970,000.00 | 196,000,000.00 | 14,900,000.00 | 351,530,000.00 | 373,070,000.00 | 0.00 | 373,070,000.00 | 327,500,000.00 | 774,020,000.00 | -314,880,000.00 | 1,088,900,000.00 | 9,425,950,000.00 | 5,816,620,000.00 | 3,609,330,000.00 | 3,360,550,000.00 | 248,780,000.00 | 0.00 |
| 2023-09-30T00:00:00 | quarterly | 344,253.00 | 83,125,599.00 | 83,469,852.00 | 2,992,000,000.00 | 8,939,000,000.00 | 18,972,000,000.00 | 6,081,000,000.00 | 8,939,000,000.00 | 1,742,000,000.00 | 17,722,000,000.00 | 18,139,000,000.00 | 18,061,000,000.00 | 339,000,000.00 | 17,722,000,000.00 | 16,887,000,000.00 | 0.00 | 0.00 | 0.00 | 835,000,000.00 | 835,000,000.00 | 6,392,000,000.00 | 1,685,000,000.00 | 0.00 | 32,000,000.00 | 1,653,000,000.00 | 1,236,000,000.00 | 417,000,000.00 | 4,707,000,000.00 | 370,000,000.00 | 1,339,000,000.00 | 506,000,000.00 | 833,000,000.00 | 0.00 | 332,000,000.00 | 2,186,000,000.00 | 0.00 | 250,000,000.00 | 1,936,000,000.00 | 24,453,000,000.00 | 13,665,000,000.00 | 59,000,000.00 | 0.00 | 462,000,000.00 | 247,000,000.00 | 247,000,000.00 | 340,000,000.00 | 8,783,000,000.00 | 3,305,000,000.00 | 5,478,000,000.00 | 3,568,000,000.00 | 0.00 | 3,568,000,000.00 | 98,000,000.00 | 3,470,000,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 10,788,000,000.00 | 217,000,000.00 | 0.00 | 0.00 | 409,000,000.00 | 0.00 | 0.00 | 12,000,000.00 | 855,000,000.00 | 0.00 | 0.00 | 9,295,000,000.00 | 8,095,000,000.00 | 1,200,000,000.00 | 0.00 | 0.00 | 50,000,000.00 |
| 2023-03-31T00:00:00 | quarterly | 427,299.00 | 82,940,578.00 | 83,367,877.00 | 4,194,950,000.00 | 7,602,670,000.00 | 19,029,690,000.00 | 5,033,320,000.00 | 7,602,670,000.00 | 1,828,240,000.00 | 16,662,980,000.00 | 17,496,320,000.00 | 16,995,450,000.00 | 332,470,000.00 | 16,662,980,000.00 | 582,640,000.00 | 118,530,000.00 | 13,505,770,000.00 | 944,330,000.00 | 833,680,000.00 | 833,680,000.00 | 6,860,170,000.00 | 2,162,640,000.00 | 0.00 | 29,410,000.00 | 2,133,230,000.00 | 1,299,890,000.00 | 833,340,000.00 | 4,697,530,000.00 | 316,000,000.00 | 2,061,720,000.00 | 528,350,000.00 | 1,533,370,000.00 | 291,350,000.00 | 291,000,000.00 | 1,742,120,000.00 | 176,150,000.00 | 4,970,000.00 | 1,561,000,000.00 | 23,855,620,000.00 | 14,124,770,000.00 | 3,690,000.00 | 136,650,000.00 | 404,240,000.00 | 264,480,000.00 | 264,480,000.00 | 0.00 | 9,060,310,000.00 | 3,581,900,000.00 | 5,478,410,000.00 | 4,049,320,000.00 | -3,751,450,000.00 | 7,800,770,000.00 | 39,150,000.00 | 4,010,000,000.00 | 3,045,930,000.00 | 4,445,860,000.00 | 269,830,000.00 | 0.00 | 9,730,850,000.00 | 160,000,000.00 | 10,490,000.00 | 301,450,000.00 | 338,060,000.00 | 0.00 | 338,060,000.00 | 229,540,000.00 | 708,240,000.00 | -345,320,000.00 | 1,053,560,000.00 | 8,143,070,000.00 | 5,505,760,000.00 | 2,637,310,000.00 | 2,502,080,000.00 | 135,230,000.00 | 0.00 |
| 2023-03-31T00:00:00 | annual | 427,299.00 | 82,940,578.00 | 83,367,877.00 | 4,194,950,000.00 | 7,602,670,000.00 | 19,029,690,000.00 | 5,033,320,000.00 | 7,602,670,000.00 | 1,828,240,000.00 | 16,662,980,000.00 | 17,496,320,000.00 | 16,995,450,000.00 | 332,470,000.00 | 16,662,980,000.00 | 582,640,000.00 | 118,530,000.00 | 13,505,770,000.00 | 944,330,000.00 | 833,680,000.00 | 833,680,000.00 | 6,860,170,000.00 | 2,162,640,000.00 | 0.00 | 29,410,000.00 | 2,133,230,000.00 | 1,299,890,000.00 | 833,340,000.00 | 4,697,530,000.00 | 316,000,000.00 | 2,061,720,000.00 | 528,350,000.00 | 1,533,370,000.00 | 291,350,000.00 | 291,000,000.00 | 1,742,120,000.00 | 176,150,000.00 | 4,970,000.00 | 1,561,000,000.00 | 23,855,620,000.00 | 14,124,770,000.00 | 3,690,000.00 | 136,650,000.00 | 404,240,000.00 | 264,480,000.00 | 264,480,000.00 | 0.00 | 9,060,310,000.00 | 3,581,900,000.00 | 5,478,410,000.00 | 4,049,320,000.00 | -3,751,450,000.00 | 7,800,770,000.00 | 39,150,000.00 | 4,010,000,000.00 | 3,045,930,000.00 | 4,445,860,000.00 | 269,830,000.00 | 0.00 | 9,730,850,000.00 | 160,000,000.00 | 10,490,000.00 | 301,450,000.00 | 338,060,000.00 | 0.00 | 338,060,000.00 | 229,540,000.00 | 708,240,000.00 | -345,320,000.00 | 1,053,560,000.00 | 8,143,070,000.00 | 5,505,760,000.00 | 2,637,310,000.00 | 2,502,080,000.00 | 135,230,000.00 | 0.00 |
| 2022-03-31T00:00:00 | annual | 582,964.00 | 82,761,913.00 | 83,344,877.00 | 5,324,350,000.00 | 5,476,160,000.00 | 18,535,970,000.00 | 3,751,630,000.00 | 5,476,160,000.00 | 1,869,150,000.00 | 15,080,770,000.00 | 16,747,440,000.00 | 15,435,370,000.00 | 354,600,000.00 | 15,080,770,000.00 | 582,860,000.00 | 161,720,000.00 | 12,089,290,000.00 | 932,400,000.00 | 833,450,000.00 | 833,450,000.00 | 8,096,830,000.00 | 3,096,950,000.00 | 1,300,000.00 | 40,390,000.00 | 3,055,260,000.00 | 1,388,590,000.00 | 1,666,670,000.00 | 4,999,880,000.00 | 346,000,000.00 | 2,269,090,000.00 | 480,560,000.00 | 1,788,530,000.00 | 270,470,000.00 | 270,000,000.00 | 1,873,860,000.00 | 368,460,000.00 | 31,560,000.00 | 1,473,840,000.00 | 23,532,200,000.00 | 14,780,690,000.00 | -148,450,000.00 | 136,370,000.00 | 370,380,000.00 | 104,010,000.00 | 104,010,000.00 | 0.00 | 9,604,610,000.00 | 4,105,570,000.00 | 5,499,040,000.00 | 4,463,360,000.00 | -2,842,150,000.00 | 7,305,510,000.00 | 159,330,000.00 | 4,154,000,000.00 | 2,832,890,000.00 | 4,043,430,000.00 | 269,860,000.00 | 0.00 | 8,751,510,000.00 | 184,000,000.00 | 13,950,000.00 | 331,680,000.00 | 525,410,000.00 | 0.00 | 525,410,000.00 | 209,970,000.00 | 853,950,000.00 | -284,660,000.00 | 1,138,610,000.00 | 6,816,550,000.00 | 3,034,600,000.00 | 3,781,950,000.00 | 3,572,230,000.00 | 209,720,000.00 | 0.00 |
| 2021-03-31T00:00:00 | annual | 721,036.00 | 83,344,877.00 | 84,065,913.00 | 1,503,660,000.00 | 11,001,910,000.00 | 12,450,590,000.00 | 8,708,850,000.00 | 11,001,910,000.00 | 1,503,660,000.00 | 12,450,590,000.00 | 12,450,590,000.00 | 12,760,150,000.00 | 309,560,000.00 | 12,450,590,000.00 | 398,000,000.00 | 200,030,000.00 | 9,810,960,000.00 | 932,400,000.00 | 833,450,000.00 | 833,450,000.00 | 3,853,150,000.00 | 1,110,300,000.00 | 1,190,000.00 | 7,550,000.00 | 1,101,560,000.00 | 1,101,560,000.00 | 0.00 | 2,742,850,000.00 | 237,000,000.00 | 402,100,000.00 | 402,100,000.00 | 0.00 | 172,170,000.00 | 172,000,000.00 | 1,547,300,000.00 | 56,580,000.00 | 49,440,000.00 | 1,441,280,000.00 | 16,613,300,000.00 | 5,161,600,000.00 | 1,240,000.00 | 28,030,000.00 | 280,230,000.00 | 39,730,000.00 | 39,730,000.00 | 0.00 | 1,448,680,000.00 | 595,080,000.00 | 853,600,000.00 | 3,133,770,000.00 | -601,930,000.00 | 3,735,700,000.00 | 75,050,000.00 | 1,575,840,000.00 | 1,989,650,000.00 | 1,924,550,000.00 | 160,260,000.00 | 0.00 | 11,451,700,000.00 | 117,000,000.00 | 13,060,000.00 | 260,600,000.00 | 425,580,000.00 | 0.00 | 425,580,000.00 | 245,200,000.00 | 667,010,000.00 | -215,340,000.00 | 882,350,000.00 | 9,840,250,000.00 | 7,397,270,000.00 | 2,442,980,000.00 | 2,181,450,000.00 | 261,530,000.00 | 0.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4,300,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: LALPATHLAB Cash Flow Data In (Cr)
| date | period_type | Free Cash Flow | Repayment Of Debt | Issuance Of Debt | Issuance Of Capital Stock | Capital Expenditure | End Cash Position | Other Cash Adjustment Outside Changein Cash | Beginning Cash Position | Changes In Cash | Financing Cash Flow | Net Other Financing Charges | Interest Paid Cff | Cash Dividends Paid | Common Stock Dividend Paid | Net Preferred Stock Issuance | Preferred Stock Issuance | Net Common Stock Issuance | Common Stock Issuance | Net Issuance Payments Of Debt | Net Long Term Debt Issuance | Long Term Debt Payments | Long Term Debt Issuance | Investing Cash Flow | Net Other Investing Changes | Interest Received Cfi | Net Investment Purchase And Sale | Sale Of Investment | Purchase Of Investment | Net Business Purchase And Sale | Purchase Of Business | Net Intangibles Purchase And Sale | Purchase Of Intangibles | Net PPE Purchase And Sale | Sale Of PPE | Purchase Of PPE | Operating Cash Flow | Taxes Refund Paid | Change In Working Capital | Change In Other Current Liabilities | Change In Other Current Assets | Change In Payable | Change In Inventory | Change In Receivables | Other Non Cash Items | Stock Based Compensation | Provisionand Write Offof Assets | Deferred Tax | Depreciation And Amortization | Amortization Cash Flow | Depreciation | Pension And Employee Benefit Expense | Gain Loss On Investment Securities | Net Foreign Currency Exchange Gain Loss | Gain Loss On Sale Of PPE | Net Income From Continuing Operations |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 4,779,000,000.00 | -1,533,370,000.00 | 0.00 | 34,880,000.00 | -574,340,000.00 | 3,609,330,000.00 | 0.00 | 2,637,310,000.00 | 972,020,000.00 | -4,138,630,000.00 | 0.00 | -293,590,000.00 | -2,011,690,000.00 | -2,011,690,000.00 | 0.00 | 0.00 | 34,880,000.00 | 34,880,000.00 | -1,533,370,000.00 | -1,533,370,000.00 | -1,533,370,000.00 | 0.00 | -242,690,000.00 | 20,120,000.00 | 453,360,000.00 | -147,050,000.00 | 9,670,730,000.00 | -9,817,780,000.00 | -3,540,000.00 | -3,540,000.00 | -62,670,000.00 | -62,670,000.00 | -502,910,000.00 | 8,760,000.00 | -511,670,000.00 | 5,353,340,000.00 | -1,320,320,000.00 | 357,390,000.00 | 93,780,000.00 | -21,560,000.00 | 304,670,000.00 | -35,010,000.00 | -71,850,000.00 | -290,120,000.00 | 217,060,000.00 | -2,730,000.00 | 1,431,580,000.00 | 1,435,970,000.00 | 601,460,000.00 | 834,510,000.00 | -4,580,000.00 | -103,970,000.00 | -1,960,000.00 | 2,180,000.00 | 3,622,930,000.00 |
| 2023-03-31T00:00:00 | annual | 4,114,610,000.00 | -1,089,790,000.00 | 0.00 | 8,720,000.00 | -445,660,000.00 | 2,637,310,000.00 | 0.00 | 3,781,950,000.00 | -1,144,640,000.00 | -2,831,830,000.00 | -1,430,000.00 | -377,230,000.00 | -1,030,130,000.00 | -1,030,130,000.00 | 0.00 | 0.00 | 8,720,000.00 | 8,720,000.00 | -1,089,790,000.00 | -1,089,790,000.00 | -1,089,790,000.00 | 0.00 | -2,873,080,000.00 | 0.00 | 306,260,000.00 | -2,560,520,000.00 | 8,786,450,000.00 | -11,346,970,000.00 | -178,190,000.00 | -178,190,000.00 | -80,510,000.00 | -80,510,000.00 | -360,120,000.00 | 5,030,000.00 | -365,150,000.00 | 4,560,270,000.00 | -1,064,340,000.00 | 354,750,000.00 | -9,340,000.00 | 32,690,000.00 | 92,270,000.00 | 187,350,000.00 | 30,900,000.00 | 39,190,000.00 | 228,110,000.00 | 75,890,000.00 | 1,027,500,000.00 | 1,501,930,000.00 | 604,140,000.00 | 897,790,000.00 | 26,120,000.00 | -64,210,000.00 | -3,840,000.00 | -8,070,000.00 | 2,410,770,000.00 |
| 2022-03-31T00:00:00 | annual | -294,000,000.00 | 0.00 | 3,454,000,000.00 | 2,000,000.00 | -4,761,000,000.00 | 3,782,000,000.00 | -10,000.00 | 2,443,000,000.00 | 1,339,000,000.00 | 1,364,000,000.00 | 0.00 | -304,000,000.00 | -1,167,000,000.00 | -1,166,600,000.00 | 0.00 | 0.00 | 2,000,000.00 | 2,000,000.00 | 3,454,000,000.00 | 3,454,000,000.00 | 0.00 | 3,454,000,000.00 | -4,492,000,000.00 | 0.00 | 496,000,000.00 | 4,333,000,000.00 | 12,809,000,000.00 | -8,476,000,000.00 | -4,576,000,000.00 | -4,576,000,000.00 | -3,820,000,000.00 | -3,820,000,000.00 | -925,000,000.00 | 16,000,000.00 | -941,000,000.00 | 4,467,000,000.00 | -1,300,000,000.00 | -167,000,000.00 | 160,000,000.00 | -177,000,000.00 | 34,000,000.00 | -100,000,000.00 | -182,000,000.00 | -170,000,000.00 | 323,000,000.00 | -13,000,000.00 | 1,246,000,000.00 | 1,081,000,000.00 | 0.00 | 1,081,000,000.00 | -17,000,000.00 | -31,000,000.00 | 0.00 | 6,000,000.00 | 3,503,000,000.00 |
| 2021-03-31T00:00:00 | annual | 3,385,600,000.00 | 0.00 | 0.00 | 2,990,000.00 | -595,900,000.00 | 2,442,980,000.00 | 0.00 | 1,967,200,000.00 | 475,780,000.00 | -1,385,560,000.00 | -10,000.00 | -158,440,000.00 | -994,830,000.00 | -994,830,000.00 | 1,500,000.00 | 1,500,000.00 | 1,490,000.00 | 1,490,000.00 | 0.00 | 0.00 | 0.00 | 0.00 | -2,120,160,000.00 | 0.00 | 396,180,000.00 | -1,893,100,000.00 | 10,687,050,000.00 | -12,580,150,000.00 | -31,500,000.00 | -31,500,000.00 | -240,260,000.00 | -240,260,000.00 | -351,480,000.00 | 4,160,000.00 | -355,640,000.00 | 3,981,500,000.00 | -1,017,010,000.00 | 366,710,000.00 | 122,350,000.00 | 17,630,000.00 | 269,200,000.00 | 144,020,000.00 | -205,080,000.00 | -283,320,000.00 | 203,740,000.00 | 48,870,000.00 | 979,300,000.00 | 771,980,000.00 | 0.00 | 771,980,000.00 | -9,240,000.00 | -47,290,000.00 | -1,160,000.00 | 1,740,000.00 | 2,964,790,000.00 |
| 2020-03-31T00:00:00 | annual | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
NSE: LALPATHLAB Income Statement Data In (Cr)
| date | period_type | Tax Effect Of Unusual Items | Tax Rate For Calcs | Normalized EBITDA | Total Unusual Items | Total Unusual Items Excluding Goodwill | Net Income From Continuing Operation Net Minority Interest | Reconciled Depreciation | Reconciled Cost Of Revenue | EBITDA | EBIT | Net Interest Income | Interest Expense | Interest Income | Normalized Income | Net Income From Continuing And Discontinued Operation | Total Expenses | Rent Expense Supplemental | Diluted Average Shares | Basic Average Shares | Diluted EPS | Basic EPS | Diluted NI Availto Com Stockholders | Net Income Common Stockholders | Otherunder Preferred Stock Dividend | Net Income | Minority Interests | Net Income Including Noncontrolling Interests | Net Income Continuous Operations | Tax Provision | Pretax Income | Other Non Operating Income Expenses | Special Income Charges | Other Special Charges | Write Off | Net Non Operating Interest Income Expense | Interest Expense Non Operating | Interest Income Non Operating | Operating Income | Operating Expense | Other Operating Expenses | Depreciation And Amortization In Income Statement | Amortization | Depreciation Income Statement | Selling General And Administration | Selling And Marketing Expense | General And Administrative Expense | Rent And Landing Fees | Gross Profit | Cost Of Revenue | Total Revenue | Operating Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31T00:00:00 | annual | 2.94 | 0.00 | 668.02 | 10.39 | 10.39 | 357.74 | 143.60 | 764.43 | 678.41 | 534.81 | 26.07 | 29.36 | 55.43 | 350.29 | 357.74 | 1,759.63 | 27.17 | 8.32 | 8.31 | 0.00 | 0.00 | 357.74 | 357.74 | 0.00 | 357.74 | -4.56 | 362.29 | 362.29 | 143.16 | 505.45 | 2.12 | -0.01 | -0.71 | 0.72 | 26.07 | 29.36 | 55.43 | 466.87 | 995.20 | 204.38 | 143.60 | 60.15 | 83.45 | 195.62 | 73.35 | 122.27 | 27.17 | 1,462.07 | 764.43 | 2,226.50 | 2,226.50 |
| 2023-03-31T00:00:00 | annual | -0.99 | 0.00 | 534.87 | -3.31 | -3.31 | 238.85 | 150.19 | 729.19 | 531.55 | 381.36 | -4.36 | 37.53 | 33.18 | 241.17 | 238.85 | 1,665.18 | 24.90 | 8.31 | 8.29 | 0.00 | 0.00 | 238.85 | 238.85 | 0.00 | 238.85 | -2.23 | 241.08 | 241.08 | 102.75 | 343.83 | 0.03 | -9.73 | -1.50 | 11.24 | -4.36 | 37.53 | 33.18 | 351.46 | 935.99 | 213.60 | 150.19 | 60.41 | 89.78 | 171.02 | 50.78 | 120.24 | 24.90 | 1,287.46 | 729.19 | 2,016.64 | 2,016.64 |
| 2022-03-31T00:00:00 | annual | 0.00 | 0.00 | 613.20 | 3.75 | 3.75 | 344.80 | 108.10 | 502.30 | 613.20 | 505.10 | -30.20 | 30.20 | 47.26 | 344.80 | 344.80 | 1,350.30 | 26.06 | 8.29 | 8.27 | 0.00 | 0.00 | 344.80 | 344.80 | 0.00 | 344.80 | -5.50 | 350.30 | 350.30 | 124.60 | 474.90 | -232.00 | 0.59 | 0.11 | -0.70 | -30.20 | 30.20 | 47.26 | 737.10 | 848.00 | 375.00 | 108.10 | 30.14 | 108.10 | 167.79 | 36.76 | 131.02 | 26.06 | 1,585.10 | 502.30 | 2,087.40 | 2,087.40 |
| 2021-03-31T00:00:00 | annual | -0.01 | 0.00 | 487.64 | -0.03 | -0.03 | 291.62 | 77.20 | 601.54 | 487.61 | 410.41 | 27.87 | 16.00 | 43.88 | 291.64 | 291.62 | 1,216.79 | 14.84 | 8.27 | 8.25 | 0.00 | 0.00 | 291.62 | 291.62 | 0.00 | 291.62 | -4.86 | 296.48 | 296.48 | 97.93 | 394.41 | 2.18 | -4.76 | -0.37 | 5.13 | 27.87 | 16.00 | 43.88 | 364.39 | 615.25 | 130.19 | 77.20 | 9.59 | 67.61 | 117.89 | 30.72 | 87.17 | 14.84 | 979.64 | 601.54 | 1,581.18 | 1,581.18 |
FII & DII Data (In Cr)
| Date | FII Gross Purchase | FII Gross Sales | FII Net Purchase / Sales | DII Gross Purchase | DII Gross Sales | DII Net Purchase / Sales |
|---|---|---|---|---|---|---|
| 2025-02-03 | 12,505.92 | 16,464.29 | -3,958.37 | 19,319.48 | 16,611.25 | 2,708.23 |
| 2025-01-30 | 10,513.63 | 15,096.58 | -4,582.95 | 13,934.35 | 11,768.46 | 2,165.89 |
| 2025-01-29 | 7,644.40 | 10,230.83 | -2,586.43 | 12,871.38 | 11,078.67 | 1,792.71 |
| 2025-01-27 | 9,488.57 | 14,504.03 | -5,015.46 | 16,503.43 | 9,861.28 | 6,642.15 |
| 2025-01-24 | 11,230.47 | 13,988.96 | -2,758.49 | 12,835.41 | 10,433.10 | 2,402.31 |
| 2025-01-23 | 13,316.55 | 18,779.07 | -5,462.52 | 14,412.73 | 10,700.18 | 3,712.55 |
| 2025-01-22 | 12,936.64 | 16,962.89 | -4,026.25 | 15,437.18 | 11,796.96 | 3,640.22 |
Piotroski F-Score
8/9
0
1
2
3
4
5
6
7
8
9
Key Metrics
EPS
48.32
P/E
61.979515
P/B
12.455707
Dividend Yield
1.02%
Market Cap
24,950.07 Cr.
Face Value
240.44
Book Value
240.44
ROE
17.11%
EBITDA Growth
615.76 Cr.
Debt/Equity
9.753
Short Term
Subscribe to unlock this feature
Medium Term
Subscribe to unlock this feature
Long Term
Subscribe to unlock this feature
Yearly Stock Performance Heatmap
Latest Updates
Ashoka Buildcon Arm Signs Rs 1,391 Crore Pact With NHAI
Ashoka Buildcon Ltd. announced on Monday, via an exchange filing, that its wholly owned subsidiary, Ashoka Bowaichandi Guskara Road Pvt Ltd., has exec...
Budget 2025: Rahul Bajoria On Addressing Income Growth And Consumption Trends
"However, discretionary, high-value consumption is taking a step back due to income growth settling at high single digits." Over the past fe...
FPIs Stay Net Sellers, Sell Stocks Worth Rs 2,575 Crore
Foreign portfolio investors stayed net sellers for the second straight session on Monday and sold stocks worth approximately Rs 2,575.1 crore, accordi...
Budget 2025: AMFI Seeks Tax Policy Reforms To Drive Mutual Fund Investments In 15-Point Proposal
The Association of Mutual Funds of India on Monday released a 15-point proposal for Union Budget 2025-26 requesting changes in tax policies that are i...
Apple iPhone SE 4: Price To Features, 11 Things You Need To Know
iPhone 16e (Not iPhone SE 4): If recent reports are to be believed, Apple may discontinue the SE label and rename iPhone SE 4 as iPhone 16e. Most Affo...
Rupee Closed Weaker Against The US Dollar
The rupee weakened by five paise to close at 85.83 against the US dollar. The Indian rupee had declined to a fresh low against the US dollar during th...
Table Space Founder Amit Banerji Dies Of Heart Attack At Age Of 45
Amit Banerji, the founder, chairman and chief executive officer of managed workspace provider Table Space, died after suffering from a heart attack, r...
War Fatigue, Economic Breakdown Or Pro-West? Why Syria's Al-Sharaa Is Seen Soft On Israel
The strategic positions have been used by Israeli forces to carry out hundreds of strikes to destroy Syria's military infrastructure. In 2011, be...
Popular Questions
What is the Market Cap of lalpathlab?
The market capitalization of Dr. Lal PathLabs Limited is ₹24,950 Cr as of 05 Feb 2025.
What are the PE and PB ratios of Dr. Lal PathLabs Limited?
The PE and PB ratios of Dr. Lal PathLabs Limited are Not Available and 12.455707 respectively as of 05 Feb 2025.
What is the 52 Week High of Dr. Lal PathLabs Limited?
The 52-week high of Dr. Lal PathLabs Limited is ₹3653.95 as of 05 Feb 2025.
What is the 52 Week Low of Dr. Lal PathLabs Limited?
The 52-week low of Dr. Lal PathLabs Limited is ₹1943.7 as of 05 Feb 2025.
What are the earnings per share (EPS) for Dr. Lal PathLabs Limited?
The Earnings Per Share (EPS) of Dr. Lal PathLabs Limited is ₹48.32 as per the most recent quarterly results available on Fincept.
What is the ROE (Return on Equity) of Dr. Lal PathLabs Limited?
The Return on Equity (ROE) of Dr. Lal PathLabs Limited is 17.11% as per the most recent financial year data. Explore more on Fincept.